Portal de Periódicos da CAPES

Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group

2022; Informa; Volume: 33; Issue: 6 Linguagem: Inglês

10.1080/09546634.2022.2079596

1471-1753

E. del Alcázar, A. López‐Ferrer, Álvaro Martínez‐Doménech, Marc Julià, Ricardo Ruíz‐Villaverde, Lourdes Rodríguez Fernández‐Freire, J. Notario, Mar Llamas‐Velasco, Marta Ferrán, J.M. Carrascosa,

Health Systems, Economic Evaluations, Quality of Life

Click to increase image sizeClick to decrease image size AcknowledgmentsWe would like to thank all the members of the Spanish Psoriasis Group who contributed patients to this series of patients treated in real-world clinical practice.Disclosure statementElena del Alcázar has served as a consultant or paid speaker for or participated in clinical trials sponsored by companies, including Abbvie, Amgen, Leo Pharma, Almirall, Janssen-Cilag, Lilly, Novartis, Sanofi, and UCB.Anna López-Ferrer has perceived consultancy/educational support/speakers honoraria and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Janssen, Leo Pharma, Lilly, MSD, Novartis, Pfizer, and UCB.Álvaro Martínez-Doménech has participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including Almirall and Janssen-Cilag.Marc Julià has served as a consultant or paid speaker for or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Amgen, Janssen-Cilag, LEO Pharma, Lilly, Novartis, and Pfizer.Ricardo Ruiz-Villaverde has received grants and research support, served as a consultant or received honoraria from Pfizer, Novartis, Lilly, Celgene, Almirall, and Abbvie.Lourdes Rodríguez Fernández-Freire has served as a consultant and speaker for AbbVie Laboratories, Janssen Pharmaceuticals Inc, MSD, Pfizer-Wyeth, Novartis, Celgene, Almirall SA, Lilly, and Leo-Pharma.Jaime Notario has served as a consultant or paid speaker for and/or participated in clinical trials sponsored by AbbVie, Almirall, Celgene, Gebro, Janssen, Leo Pharma, Lilly, MSD, Novartis, and Pfizer.M. Llamas-Velasco has a potential conflict of interests (advisory board member, consultant, research support, participation in clinical trials, and honorary for speaking) with the following pharmaceutical companies: Abbvie, Amgen, Janssen-Cilag, Leo Pharma, Novartis, Lilly, and Celgene.Marta Ferran has received grants and research support, served as a consultant or received honoraria from Abbvie, Pfizer, Janssen, Novartis, Lilly, Almirall, Leo, and Celgene.José Manuel Carrascosa has participated as PI/SI, and/or member of steering committees and/or advisor and/or invited speaker for Celgene, Amgen, Abbvie, Almirall, Novartis, Leo-Pharma, Lilly, Sandoz, Mylan, and Janssen.None of the aforementioned has any relation to the present work.